Search results
Results from the WOW.Com Content Network
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
AstraZeneca then used those studies and articles as the basis for promotional messages about unapproved uses of Seroquel." [96] Multiple lawsuits have been filed in relation to quetiapine's side-effects, in particular, diabetes. [101] [102] [103] [104]
Seroquel: False Claims Act 2007 Bristol-Myers Squibb [18] $515 million Off-label promotion, kickbacks, Medicare fraud Abilify, Serzone: False Claims Act, FDCA 2002 Schering-Plough [19] $500 million Poor manufacturing practices Claritin: FDA Current Good Manufacturing Practices: 2006 Mylan [20] $465 million Misclassification under the Medicaid ...
Still, the suit focused on diabetes, and the complaint Sheller wrote was a hodgepodge of weak claims, in large part because the boy had also taken the Risperdal competitor drug Seroquel. Its manufacturer, AstraZeneca, was also named as a defendant, as was the boy’s doctor, who was accused of malpractice.
AstraZeneca (AZN) told American doctors the company's antipsychotic drug Seroquel AstraZeneca sales-rep notes reveal troubling relationship with doctors Skip to main content
Seroquel: AstraZeneca [15] $520,000,000 $520 million (civil only) Off-label promotion/kickbacks False Claims Act 2007 12 11 Abilify/Serzone: Bristol-Myers Squibb [16] $540,000,000 $515 million ($25 million in civil disgorgement) Off-label promotion/ kickbacks/Medicare fraud False Claims Act/FDCA 2016 14 (tie) 12 EpiPen (epinephrine) Mylan [17 ...
Lighter Side. Politics. Science & Tech. Sports. Weather. 24/7 Help. ... Many of these cases have lead to class action lawsuits and proceedings by the Federal Trade Commision (FTC), resulting in a ...
In addition, Astrazeneca faces numerous personal-injury lawsuits from former users of Seroquel (quetiapine), amidst federal investigations of its marketing practices. [106] By expanding the conditions for which they were indicated, Astrazeneca's Seroquel and Eli Lilly's Zyprexa had become the biggest selling antipsychotics in 2008 with global ...